Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease

Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease

Item
http://www.wikidata.org/entity/Q35550630
Epidemiology, management, and economic evaluation of screening of gallstone disease among type 2 diabetics: A systematic reviewEzetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)The ABCG5 ABCG8 sterol transporter opposes the development of fatty liver disease and loss of glycemic control independently of phytosterol accumulationAntilithiasic and hypolipidaemic effects of Raphanus sativus L. var. niger on mice fed with a lithogenic diet.Current views on genetics and epigenetics of cholesterol gallstone diseaseEzetimibe markedly attenuates hepatic cholesterol accumulation and improves liver function in the lysosomal acid lipase-deficient mouse, a model for cholesteryl ester storage disease.New insights into the molecular mechanism of intestinal fatty acid absorption.Quantitation of the rates of hepatic and intestinal cholesterol synthesis in lysosomal acid lipase-deficient mice before and during treatment with ezetimibe.Interval increase in the prevalence of symptomatic cholelithiasis-associated non-alcoholic fatty liver disease over a ten-year period in an Asian population.The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial.Phyllanthus Niruri Standardized Extract Alleviates the Progression of Non-Alcoholic Fatty Liver Disease and Decreases Atherosclerotic Risk in Sprague-Dawley Rats.Potential Therapeutic Agents for the Treatment of Fatty Degeneration of Liver and Atheromatous Plaques: An Experimental Study in Rats.Limits and perspective of oral therapy with statins and aspirin for the prevention of symptomatic cholesterol gallstone disease.Peroxisome Proliferator-Activated Receptor- Prevents Cholesterol Gallstone Formation in C57bl Mice by Regulating Bile Acid Synthesis and Enterohepatic CirculationRecent advances in understanding and managing cholesterol gallstones
P2860

Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease

Item
http://www.wikidata.org/entity/Q35550630
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Ezetimibe: its novel effects o ...... nalcoholic Fatty liver disease
@ast
Ezetimibe: its novel effects o ...... nalcoholic Fatty liver disease
@en
type
label
Ezetimibe: its novel effects o ...... nalcoholic Fatty liver disease
@ast
Ezetimibe: its novel effects o ...... nalcoholic Fatty liver disease
@en
prefLabel
Ezetimibe: its novel effects o ...... nalcoholic Fatty liver disease
@ast
Ezetimibe: its novel effects o ...... nalcoholic Fatty liver disease
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P478
P577
P5875
P698
P932
P356
P1433
P1476
Ezetimibe: its novel effects o ...... nalcoholic Fatty liver disease
@en
P2093
P2860
P304
P31
P356
P478
P577
P5875
P698
P932